Cisplatin-Induced Hearing Loss (CIHL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Cisplatin-Induced Hearing Loss (CIHL) Market Outlook

Thelansis’s “Cisplatin-Induced Hearing Loss (CIHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cisplatin-Induced Hearing Loss (CIHL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cisplatin-Induced Hearing Loss (CIHL) Overview

Cisplatin-induced hearing loss (CIHL) is favored either by pre-existing afflictions like hypoalbuminemia, anemia, renal failure, and noise-induced hearing loss or by risk factors like therapy with loop diuretics, aminoglycoside antibiotics, radiotherapy fields which includes the inner ear, extreme ages (very young or very old), duration and dose schedule of cisplatin infusion, and genetic factors. Between 11% and 97% of patients treated with cisplatin develop hearing loss, with an average incidence of 62%. Cisplatin-induced tinnitus is not an infrequent occurrence either. Ototoxicity may occur within hours to days after cisplatin administration. Cisplatin inflicts injuries mainly to outer hair cells, progressing from the third to the first row and to some extent to inner hair cells of the organ of Corti in the basal turn of the cochlea followed by alterations in sensorial cells situated in the apex. Cisplatin also targets supporting cells, marginal cells of the stria vascularis, and the spiral ligament. The vestibular organs are not spared, nor are spiral ganglion cells in experimental conditions. The ensuing hearing loss may be very disabling to patients whose communication is already impaired due to cancers of the head and neck. Hearing loss is also a common cause of depression and reduction of the quality of life.

• According to a literature survey, the Incidence of CIHL was estimated to be 50-60% of children treated with cisplatin, and 5-20% of those treated with carboplatin acquire some degree of irreversible hearing loss. The incidence increases to 80% - 90% in those receiving cisplatin and myeloablative carboplatin.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: